CD19 and acute lymphoblastic leukemia: Patient ALL_H0118 was treated for a normal-karyotype, multiply relapsed ALL and experienced mild CRS with transient in vivo CAR-T expansion, but persistent leukaemia at day 28 despite presence of CD19 CAR T cells (0.2% in peripheral blood).